Phase 1 Study to Assess Safety and Efficacy of ANG003

NCT06052293 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Exocrine Pancreatic Insufficiency

Interventions

DRUG: ANG003

Sponsor

Anagram Therapeutics, Inc.